This HTML5 document contains 69 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n19http://linked.opendata.cz/resource/drugbank/drug/DB00017/identifier/genbank/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00017/identifier/uniprotkb/
n25http://linked.opendata.cz/resource/AHFS/
n16http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n4http://linked.opendata.cz/resource/drugbank/company/
n27http://linked.opendata.cz/resource/drugbank/drug/DB00017/identifier/pharmgkb/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00017/identifier/wikipedia/
n10http://linked.opendata.cz/resource/drugbank/dosage/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00017/identifier/kegg-compound/
n9http://bio2rdf.org/drugbank:
n17http://linked.opendata.cz/resource/drugbank/drug/DB00017/identifier/kegg-drug/
admshttp://www.w3.org/ns/adms#
n14http://linked.opendata.cz/resource/drugbank/drug/DB00017/identifier/drugbank/
n11http://linked.opendata.cz/resource/drugbank/patent/
n26http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n15http://linked.opendata.cz/ontology/mesh/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00017/identifier/national-drug-code-directory/
n3http://linked.opendata.cz/ontology/drugbank/
n23http://www.rxlist.com/cgi/generic2/
n12http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n24http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00017
rdf:type
n3:Drug
n3:description
Synthetic peptide, 32 residues long formulated as a nasal spray.
n3:dosage
n10:271B3FA1-363D-11E5-9242-09173F13E4C5 n10:271B3FA2-363D-11E5-9242-09173F13E4C5 n10:271B3FA0-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Sanofi-Aventis Canada Inc. Calcimar Solution. Laval, Quebec: N.p., 2014. #Lexicomp. Calcitonin. N.p., 2014. Web. 11 Nov. 2014.
n3:group
approved investigational
n3:halfLife
Half-life elimination (terminal): I.M. 58 minutes; SubQ 59 to 64 minutes; Nasal: ~18 to 23 minutes
n3:indication
Used in the treatment of symptomatic Paget's disease for patients unresponsive to alternate treatments or intolerant to such treatments. In addition, it is used in emergency situations when serum calcium levels must be decreased quickly until the underlying condition is identified. It can also be added to existing therapeutic regimens for hypercalcemia such as intravenous fluids and furosemide, oral phosphate or corticosteroids, or other agents. Calcitonin can be used in patients with azotemia and cases where intravenous fluids would be contraindicated due to limited cardiac reserves. Also for the treatment of post-menopausal osteoporosis in women more than 5 years post-menopause.
n3:manufacturer
n4:271B3F95-363D-11E5-9242-09173F13E4C5 n4:271B3F96-363D-11E5-9242-09173F13E4C5 n4:271B3F93-363D-11E5-9242-09173F13E4C5 n4:271B3F94-363D-11E5-9242-09173F13E4C5 n4:271B3F92-363D-11E5-9242-09173F13E4C5 n4:271B3F91-363D-11E5-9242-09173F13E4C5
owl:sameAs
n9:DB00017 n26:DB00017
dcterms:title
Salmon Calcitonin
adms:identifier
n7:Calcitonin n13:P01263 n14:DB00017 n17:D00249 n18:60505-0823-6 n19:Y00765 n21:C06865 n27:PA448715
n3:mechanismOfAction
Calcitonin binds to the calcitonin receptor (found primarily in osteoclasts) which then enhances the production of vitamin D producing enzymes (25-hydroxyvitamine D-24-hydroxylase), leading to greater calcium retention and enhanced bone density. Binding of calcitonin to its receptor also activates adenylyl cyclase and the phosphatidyl-inositol-calcium pathway.
n3:packager
n4:271B3F8E-363D-11E5-9242-09173F13E4C5 n4:271B3F8F-363D-11E5-9242-09173F13E4C5 n4:271B3F8C-363D-11E5-9242-09173F13E4C5 n4:271B3F8D-363D-11E5-9242-09173F13E4C5 n4:271B3F90-363D-11E5-9242-09173F13E4C5
n3:patent
n11:6440392 n11:5733569
n3:routeOfElimination
Urine. Studies with injectable calcitonin show increases in the excretion of filtered phosphate, calcium, and sodium by decreasing their tubular reabsorption in the kidney.
n3:synonym
Miacalcin Cibacalcin Calcitonin-salmon Salmotonin Fortical Calcitonin 1 precursor Calcimar Calcitonin, salmon Salmon calcitonin
n3:toxicity
Salmon calcitonin was shown to inhibit lactation in animals and is not recommend in nursing mothers. While research in animals have shown a decrease in fetal weight, no studies have yet shown similar results in humans. It is recommended however to proceed carefully when administering salmon calcitonin to pregnant women and consider if the benefits outweigh the risks. Because of its protein nature, salmon calcitonin may provoke an allergy reaction (bronchospams and swelling of the tongue/throat) that can turn into a full-blown anaphylactic response. The manufacturer also reports an increase in the risk of malignancies from oral route (0.7%) to intranasal route (2.4%) compared to placebo. The same may apply to IV, IM and SC routes since the systemic exposure is higher in those cases. Nausea is noticeable in some patients but tends to decrease with continued administration. Rhinitis, headaches and back pain have also been reported among others.
n3:volumeOfDistribution
0.15 to 0.3 L/kg
n24:hasAHFSCode
n25:68-24-00
n3:proteinBinding
30 to 40%
n3:synthesisReference
Marcos C. Poblet, Berta P. Obiols, Gemma J. Farres, "Procedure for preparing salmon calcitonin." U.S. Patent US5527881, issued October, 1991.
n15:hasConcept
n16:M0092392
foaf:page
n23:calcit.htm
n3:Molecular-Formula
n12:271B3FA6-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n12:271B3FA5-363D-11E5-9242-09173F13E4C5
n3:absorption
Salmon calcitonin is rapidly absorbed and eliminated. Bioavailability following subcutaneous and intramuscular injection in humans is high and similar for the two routes of administration (71% and 66%, respectively). Via the nasal route, the bioavailability varies between 3 to 5% relative to IM.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
47931-85-1
n3:category
n3:containedIn
n5:271B3F98-363D-11E5-9242-09173F13E4C5 n5:271B3F99-363D-11E5-9242-09173F13E4C5 n5:271B3F97-363D-11E5-9242-09173F13E4C5 n5:271B3F9E-363D-11E5-9242-09173F13E4C5 n5:271B3F9F-363D-11E5-9242-09173F13E4C5 n5:271B3F9C-363D-11E5-9242-09173F13E4C5 n5:271B3F9D-363D-11E5-9242-09173F13E4C5 n5:271B3F9A-363D-11E5-9242-09173F13E4C5 n5:271B3F9B-363D-11E5-9242-09173F13E4C5
n3:Hydrophobicity
n12:271B3FA3-363D-11E5-9242-09173F13E4C5
n3:Isoelectric-Point
n12:271B3FA4-363D-11E5-9242-09173F13E4C5